1 5599 154 ROLES OF THE NEURON-RESTRICTIVE SILENCER FACTOR IN THE PATHOPHYSIOLOGICAL PROCESS OF THE CENTRAL NERVOUS SYSTEM. THE NEURON-RESTRICTIVE SILENCER FACTOR (NRSF), ALSO KNOWN AS REPRESSOR ELEMENT 1 (RE-1) SILENCING TRANSCRIPTION FACTOR (REST) OR X2 BOX REPRESSOR (XBR), IS A ZINC FINGER TRANSCRIPTION FACTOR THAT IS WIDELY EXPRESSED IN NEURONAL AND NON-NEURONAL CELLS. IT IS A MASTER REGULATOR OF THE NERVOUS SYSTEM, AND THE FUNCTION OF NRSF IS THE BASIS OF NEURONAL DIFFERENTIATION, DIVERSITY, PLASTICITY, AND SURVIVAL. NRSF CAN BIND TO THE NEURON-RESTRICTIVE SILENCER ELEMENT (NRSE), RECRUIT SOME CO-REPRESSORS, AND THEN INHIBIT TRANSCRIPTION OF NRSE DOWNSTREAM GENES THROUGH EPIGENETIC MECHANISMS. IN NEUROGENESIS, NRSF FUNCTIONS NOT ONLY AS A TRANSCRIPTIONAL SILENCER THAT CAN MEDIATE THE TRANSCRIPTIONAL INHIBITION OF NEURON-SPECIFIC GENES IN NON-NEURONAL CELLS AND THUS GIVE NEURON CELLS SPECIFICITY, BUT ALSO AS A TRANSCRIPTIONAL ACTIVATOR TO INDUCE NEURONAL DIFFERENTIATION. MANY STUDIES HAVE CONFIRMED THE ASSOCIATION BETWEEN NRSF AND BRAIN DISORDERS, SUCH AS BRAIN INJURY AND NEURODEGENERATIVE DISEASES. OVEREXPRESSION, UNDEREXPRESSION, OR MUTATION MAY LEAD TO NEUROLOGICAL DISORDERS. IN TUMORIGENESIS, NRSF FUNCTIONS AS AN ONCOGENE IN NEURONAL TUMORS, SUCH AS NEUROBLASTOMAS, MEDULLOBLASTOMAS, AND PHEOCHROMOCYTOMAS, STIMULATING THEIR PROLIFERATION, WHICH RESULTS IN POOR PROGNOSIS. ADDITIONALLY, NRSF-MEDIATED SELECTIVE TARGETS GENE REPRESSION PLAYS AN IMPORTANT ROLE IN THE DEVELOPMENT AND MAINTENANCE OF NEUROPATHIC PAIN CAUSED BY NERVE INJURY, CANCER, AND DIABETES. AT PRESENT, SEVERAL COMPOUNDS THAT TARGET NRSF OR ITS CO-REPRESSORS, SUCH AS REST-VP16 AND X5050, HAVE BEEN SHOWN TO BE CLINICALLY EFFECTIVE AGAINST MANY BRAIN DISEASES, SUCH AS SEIZURES, IMPLYING THAT NRSF AND ITS CO-REPRESSORS MAY BE POTENTIAL AND PROMISING THERAPEUTIC TARGETS FOR NEURAL DISORDERS. IN THE PRESENT REVIEW, WE INTRODUCED THE BIOLOGICAL CHARACTERISTICS OF NRSF; REVIEWED THE PROGRESS TO DATE IN UNDERSTANDING THE ROLES OF NRSF IN THE PATHOPHYSIOLOGICAL PROCESSES OF THE NERVOUS SYSTEM, SUCH AS NEUROGENESIS, BRAIN DISORDERS, NEURAL TUMORIGENESIS, AND NEUROPATHIC PAIN; AND SUGGESTED NEW THERAPEUTIC APPROACHES TO SUCH BRAIN DISEASES. 2022 2 5064 38 PHOSPHORYLATION OF RELA/P65 PROMOTES DNMT-1 RECRUITMENT TO CHROMATIN AND REPRESSES TRANSCRIPTION OF THE TUMOR METASTASIS SUPPRESSOR GENE BRMS1. THE MAJORITY OF PATIENTS WITH LUNG CANCER PRESENT WITH METASTATIC DISEASE. CHRONIC INFLAMMATION AND SUBSEQUENT ACTIVATION OF NUCLEAR FACTOR-KAPPAB (NF-KAPPAB) HAVE BEEN ASSOCIATED WITH THE DEVELOPMENT OF CANCERS. THE RELA/P65 SUBUNIT OF NF-KAPPAB IS TYPICALLY ASSOCIATED WITH TRANSCRIPTIONAL ACTIVATION. IN THIS REPORT WE SHOW THAT RELA/P65 CAN FUNCTION AS AN ACTIVE TRANSCRIPTIONAL REPRESSOR THROUGH ENHANCED METHYLATION OF THE BRMS1 (BREAST CANCER METASTASIS SUPPRESSOR 1) METASTASIS SUPPRESSOR GENE PROMOTER VIA DIRECT RECRUITMENT OF DNMT-1 (DNA (CYTOSINE-5)-METHYLTRANSFERASE 1) TO CHROMATIN IN RESPONSE TO TUMOR NECROSIS FACTOR (TNF). TNF-MEDIATED PHOSPHORYLATION OF S276 ON RELA/P65 IS REQUIRED FOR RELA/P65-DNMT-1 INTERACTIONS, CHROMATIN LOADING OF DNMT-1 AND SUBSEQUENT BRMS1 PROMOTER METHYLATION AND TRANSCRIPTIONAL REPRESSION. THE ABILITY OF RELA/P65 TO FUNCTION AS AN ACTIVE TRANSCRIPTIONAL REPRESSOR IS PROMOTER SPECIFIC, AS THE NF-KAPPAB-REGULATED GENE CIAP2 (CELLULAR INHIBITOR OF APOPTOSIS 2) IS TRANSCRIPTIONALLY ACTIVATED WHEREAS BRMS1 IS REPRESSED UNDER IDENTICAL CONDITIONS. SMALL-MOLECULE INHIBITION OF EITHER OF THE MINIMAL INTERACTING DOMAINS BETWEEN RELA/P65-DNMT-1 AND RELA/P65-BRMS1 PROMOTER ABROGATES BRMS1 METHYLATION AND ITS TRANSCRIPTIONAL REPRESSION. THE ABILITY OF RELA/P65 TO DIRECTLY RECRUIT DNMT-1 TO CHROMATIN, RESULTING IN PROMOTER-SPECIFIC METHYLATION AND TRANSCRIPTIONAL REPRESSION OF TUMOR METASTASIS SUPPRESSOR GENE BRMS1, HIGHLIGHTS A NEW MECHANISM THROUGH WHICH NF-KAPPAB CAN REGULATE METASTATIC DISEASE, AND OFFERS A POTENTIAL TARGET FOR NEWER-GENERATION EPIGENETIC ONCOPHARMACEUTICALS. 2012 3 4765 62 NRSF AND ITS EPIGENETIC EFFECTORS: NEW TREATMENTS FOR NEUROLOGICAL DISEASE. THE NEURON RESTRICTIVE SILENCER FACTOR (NRSF) IS THE WELL-KNOWN MASTER TRANSCRIPTIONAL REPRESSOR OF THE NEURONAL PHENOTYPE. RESEARCH TO DATE HAS SHOWN THAT IT IS AN IMPORTANT PLAYER IN THE GROWTH AND DEVELOPMENT OF THE NERVOUS SYSTEM. ITS ROLE IN THE MATURATION OF NEURAL PRECURSOR CELLS TO ADULT NEURONS HAS BEEN WELL CHARACTERIZED IN STEM CELL MODELS. WHILE MUCH HAS BEEN CHARACTERIZED FROM A DEVELOPMENTAL PERSPECTIVE, RESEARCH IS REVEALING THAT NRSF PLAYS A ROLE IN VARIOUS NEUROLOGICAL DISEASES, RANGING FROM NEURODEGENERATIVE, NEUROPSYCHIATRIC, TO CANCER. DYSREGULATION OF NRSF ACTIVITY DISRUPTS DOWNSTREAM GENE EXPRESSION THAT IS RESPONSIBLE FOR NEURONAL CELL HOMEOSTASIS IN SEVERAL MODELS THAT CONTRIBUTE TO PATHOLOGIC STATES. INTERESTINGLY, IT IS NOW BECOMING APPARENT THAT THE DYSREGULATION OF NRSF CONTRIBUTES TO NEUROLOGICAL DISEASE THROUGH EPIGENETIC MECHANISMS. ALTHOUGH NRSF ITSELF IS A TRANSCRIPTION FACTOR, ITS MAJOR EFFECTORS ARE CHROMATIN MODIFIERS. AT THE LEVEL OF EPIGENETICS, CHANGES IN NRSF ACTIVITY HAVE BEEN WELL CHARACTERIZED IN MODELS OF NEUROPATHIC PAIN AND EPILEPSY. BETTER UNDERSTANDING OF THE EPIGENETIC BASIS OF BRAIN DISEASES HAS LED TO DESIGN AND USE OF SMALL MOLECULES THAT CAN PREVENT NRSF FROM REPRESSING GENE EXPRESSION BY NEUTRALIZING ITS INTERACTIONS WITH ITS CHROMATIN REMODELERS. THIS REVIEW WILL ADDRESS THE BASIC FUNCTION OF NRSF AND ITS COFACTORS, INVESTIGATE THEIR MECHANISMS, THEN EXPLORE HOW THEIR DYSFUNCTION CAN CAUSE DISEASE STATES. THIS REVIEW WILL ALSO ADDRESS RESEARCH ON NRSF AS A THERAPEUTIC TARGET AND DELVE INTO NEW THERAPEUTIC STRATEGIES THAT FOCUS ON DISRUPTING NRSF'S ABILITY TO RECRUIT CHROMATIN REMODELERS. 2018 4 2144 31 EPIGENETIC LANDSCAPE OF STRESS SURFEIT DISORDERS: KEY ROLE FOR DNA METHYLATION DYNAMICS. CHRONIC EXPOSURE TO STRESS THROUGHOUT LIFESPAN ALTERS BRAIN STRUCTURE AND FUNCTION, INDUCING A MALADAPTIVE RESPONSE TO ENVIRONMENTAL STIMULI, THAT CAN CONTRIBUTE TO THE DEVELOPMENT OF A PATHOLOGICAL PHENOTYPE. STUDIES HAVE SHOWN THAT HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS DYSFUNCTION IS ASSOCIATED WITH VARIOUS NEUROPSYCHIATRIC DISORDERS, INCLUDING MAJOR DEPRESSIVE, ALCOHOL USE AND POST-TRAUMATIC STRESS DISORDERS. DOWNSTREAM ACTORS OF THE HPA AXIS, GLUCOCORTICOIDS ARE CRITICAL MEDIATORS OF THE STRESS RESPONSE AND EXERT THEIR FUNCTION THROUGH SPECIFIC RECEPTORS, I.E., THE GLUCOCORTICOID RECEPTOR (GR), HIGHLY EXPRESSED IN STRESS/REWARD-INTEGRATIVE PATHWAYS. GRS ARE LIGAND-ACTIVATED TRANSCRIPTION FACTORS THAT RECRUIT EPIGENETIC ACTORS TO REGULATE GENE EXPRESSION VIA DNA METHYLATION, ALTERING CHROMATIN STRUCTURE AND THUS SHAPING THE RESPONSE TO STRESS. THE DYNAMIC INTERPLAY BETWEEN STRESS RESPONSE AND EPIGENETIC MODIFIERS SUGGEST DNA METHYLATION PLAYS A KEY ROLE IN THE DEVELOPMENT OF STRESS SURFEIT DISORDERS. 2021 5 5938 40 TARGETING INDUCIBLE EPIGENETIC REPROGRAMMING PATHWAYS IN CHRONIC AIRWAY REMODELING. ALLERGIC ASTHMA IS A CHRONIC INFLAMMATORY AIRWAY DISEASE WHOSE CLINICAL COURSE IS PUNCTUATED BY ACUTE EXACERBATIONS FROM AEROALLERGEN EXPOSURE OR RESPIRATORY VIRUS INFECTIONS. AEROALLERGENS AND RESPIRATORY VIRUSES STIMULATE TOLL-LIKE RECEPTOR (TLR) SIGNALING, PRODUCING OXIDATIVE INJURY AND INFLAMMATION. REPETITIVE EXACERBATIONS PRODUCE COMPLEX MUCOSAL ADAPTATIONS, CELL-STATE CHANGES, AND STRUCTURAL REMODELING. THESE STRUCTURAL CHANGES PRODUCE SUBSTANTIAL MORBIDITY, DECREASE LUNG CAPACITY, AND IMPAIR QUALITY OF LIFE. WE WILL REVIEW RECENT SYSTEMS-LEVEL STUDIES THAT PROVIDE FUNDAMENTAL NEW INSIGHTS INTO HOW REPETITIVE ACTIVATION OF INNATE SIGNALING PATHWAYS PRODUCE EPIGENETIC 'TRAINING' TO INDUCE ADAPTIVE EPITHELIAL RESPONSES. OXIDATIVE STRESS PRODUCED DOWNSTREAM OF TLR SIGNALING INDUCES TRANSIENT OXIDATION OF GUANINE BASES IN THE REGULATORY REGIONS OF INFLAMMATORY GENES. THE EPIGENETIC MARK 8-OXOG IS BOUND BY A PLEIOTROPIC DNA REPAIR ENZYME, 8-OXOGUANINE DNA GLYCOSYLASE (OGG1), WHICH INDUCES CONFORMATIONAL CHANGES IN ADJACENT DNA TO RECRUIT THE NFKAPPAB.BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) COMPLEX. THE NFKAPPAB.BRD4 COMPLEX NOT ONLY PLAYS A CENTRAL ROLE IN INFLAMMATION, BUT ALSO TRIGGERS MESENCHYMAL TRANSITION AND EXTRACELLULAR MATRIX REMODELING. SMALL MOLECULE INHIBITORS OF OGG1-8-OXOG BINDING AND BRD4-ACETYLATED HISTONE INTERACTION HAVE BEEN DEVELOPED. WE PRESENT STUDIES DEMONSTRATING EFFICACY OF THESE IN REDUCING AIRWAY INFLAMMATION IN PRECLINICAL MODELS. TARGETING INDUCIBLE EPIGENETIC REPROGRAMMING PATHWAY SHOWS PROMISE FOR THERAPEUTICS IN REVERSING AIRWAY REMODELING IN A VARIETY OF CHRONIC AIRWAY DISEASES. 2019 6 2414 36 EPIGENETIC SIGNALING IN PSYCHIATRIC DISORDERS. PSYCHIATRIC DISORDERS ARE COMPLEX MULTIFACTORIAL ILLNESSES INVOLVING CHRONIC ALTERATIONS IN NEURAL CIRCUIT STRUCTURE AND FUNCTION. WHILE GENETIC FACTORS ARE IMPORTANT IN THE ETIOLOGY OF DISORDERS SUCH AS DEPRESSION AND ADDICTION, RELATIVELY HIGH RATES OF DISCORDANCE AMONG IDENTICAL TWINS CLEARLY INDICATE THE IMPORTANCE OF ADDITIONAL MECHANISMS. ENVIRONMENTAL FACTORS SUCH AS STRESS OR PRIOR DRUG EXPOSURE ARE KNOWN TO PLAY A ROLE IN THE ONSET OF THESE ILLNESSES. SUCH EXPOSURE TO ENVIRONMENTAL INSULTS INDUCES STABLE CHANGES IN GENE EXPRESSION, NEURAL CIRCUIT FUNCTION, AND ULTIMATELY BEHAVIOR, AND THESE MALADAPTATIONS APPEAR DISTINCT BETWEEN DEVELOPMENTAL AND ADULT EXPOSURES. INCREASING EVIDENCE INDICATES THAT THESE SUSTAINED ABNORMALITIES ARE MAINTAINED BY EPIGENETIC MODIFICATIONS IN SPECIFIC BRAIN REGIONS. INDEED, TRANSCRIPTIONAL DYSREGULATION AND ASSOCIATED ABERRANT EPIGENETIC REGULATION IS A UNIFYING THEME IN PSYCHIATRIC DISORDERS. ASPECTS OF DEPRESSION AND ADDICTION CAN BE MODELED IN ANIMALS BY INDUCING DISEASE-LIKE STATES THROUGH ENVIRONMENTAL MANIPULATIONS (E.G., CHRONIC STRESS, DRUG ADMINISTRATION). UNDERSTANDING HOW ENVIRONMENTAL FACTORS RECRUIT THE EPIGENETIC MACHINERY IN ANIMAL MODELS REVEALS NEW INSIGHT INTO DISEASE MECHANISMS IN HUMANS. 2014 7 2415 36 EPIGENETIC SIGNALING IN PSYCHIATRIC DISORDERS: STRESS AND DEPRESSION. PSYCHIATRIC DISORDERS ARE COMPLEX MULTIFACTORIAL DISORDERS INVOLVING CHRONIC ALTERATIONS IN NEURAL CIRCUIT STRUCTURE AND FUNCTION. WHILE GENETIC FACTORS PLAY A ROLE IN THE ETIOLOGY OF DISORDERS SUCH AS DEPRESSION, ADDICTION, AND SCHIZOPHRENIA, RELATIVELY HIGH RATES OF DISCORDANCE AMONG IDENTICAL TWINS CLEARLY POINT TO THE IMPORTANCE OF ADDITIONAL FACTORS. ENVIRONMENTAL FACTORS, SUCH AS STRESS, PLAY A MAJOR ROLE IN THE PSYCHIATRIC DISORDERS BY INDUCING STABLE CHANGES IN GENE EXPRESSION, NEURAL CIRCUIT FUNCTION, AND ULTIMATELY BEHAVIOR. INSULTS AT THE DEVELOPMENTAL STAGE AND IN ADULTHOOD APPEAR TO INDUCE DISTINCT MALADAPTATIONS. INCREASING EVIDENCE INDICATES THAT THESE SUSTAINED ABNORMALITIES ARE MAINTAINED BY EPIGENETIC MODIFICATIONS IN SPECIFIC BRAIN REGIONS. INDEED, TRANSCRIPTIONAL DYSREGULATION AND ASSOCIATED ABERRANT EPIGENETIC REGULATION IS A UNIFYING THEME IN PSYCHIATRIC DISORDERS. ASPECTS OF DEPRESSION CAN BE MODELED IN ANIMALS BY INDUCING DISEASE-LIKE STATES THROUGH ENVIRONMENTAL MANIPULATIONS, AND THESE STUDIES CAN PROVIDE A MORE GENERAL UNDERSTANDING OF EPIGENETIC MECHANISMS IN PSYCHIATRIC DISORDERS. UNDERSTANDING HOW ENVIRONMENTAL FACTORS RECRUIT THE EPIGENETIC MACHINERY IN ANIMAL MODELS IS PROVIDING NEW INSIGHTS INTO DISEASE MECHANISMS IN HUMANS. 2014 8 2305 42 EPIGENETIC REGULATION OF CC-CHEMOKINE LIGAND 2 IN NONRESOLVING INFLAMMATION. INFLAMMATION MEDIATED BY THE CROSSTALK BETWEEN LEUKOCYTES AND RESIDENT TISSUE CELLS IS CRUCIAL FOR THE MAINTENANCE OF HOMEOSTASIS. BECAUSE CHEMOKINE LIGANDS AND RECEPTORS, WHICH RECRUIT A VARIETY OF LEUKOCYTES, ARE WIDELY DISTRIBUTED AMONG TISSUES, IT IS IMPORTANT TO UNDERSTAND THE MECHANISMS REGULATING INFLAMMATORY DISEASE. CHEMOKINES SUCH AS CC-CHEMOKINE LIGAND 2 (CCL2) AMPLIFY AND MAINTAIN INFLAMMATION THROUGH CHEMOKINE-CYTOKINE NETWORKS AFTER THE RECRUITMENT OF CIRCULATING LEUKOCYTES. CHEMOKINE-DEPENDENT NONRESOLVING INFLAMMATION OCCURS IN THE PERIPHERAL AND CENTRAL NERVOUS SYSTEMS, AND UNDERLIES SEVERAL INTRACTABLE DISEASES, INCLUDING CANCER AND NEUROPATHIC PAIN. THE CHRONIC UPREGULATION OF CHEMOKINES IS OFTEN MEDIATED BY EPIGENETIC MECHANISMS CONSISTING OF DNA METHYLATION, HISTONE MODIFICATION, AND NUCLEOSOME POSITIONING. IN PARTICULAR, HISTONE ACETYLATION AND METHYLATION HAVE BEEN SHOWN TO PLAY IMPORTANT ROLES IN THE UPREGULATION OF CHEMOKINE EXPRESSION. IN ADDITION TO CCL2, SEVERAL OTHER CHEMOKINES STRONGLY CONTRIBUTE TO NEUROPATHIC PAIN THROUGH EPIGENETIC INDUCTION. CONSEQUENTLY, TARGETING EPIGENETIC CHANGES MAY HAVE THERAPEUTIC POTENTIAL FOR NONRESOLVING INFLAMMATORY DISEASES SUCH AS NEUROPATHIC PAIN. FURTHER RESEARCH INTO THE EPIGENETICS OF INFLAMMATORY DISEASES SHOULD PROMOTE THE DEVELOPMENT OF NOVEL AND EFFECTIVE TREATMENT STRATEGIES FOR INTRACTABLE INFLAMMATORY DISEASES. 2014 9 6517 26 TRANSCRIPTIONAL AND EPIGENETIC MECHANISMS OF ADDICTION. INVESTIGATIONS OF LONG-TERM CHANGES IN BRAIN STRUCTURE AND FUNCTION THAT ACCOMPANY CHRONIC EXPOSURE TO DRUGS OF ABUSE SUGGEST THAT ALTERATIONS IN GENE REGULATION CONTRIBUTE SUBSTANTIALLY TO THE ADDICTIVE PHENOTYPE. HERE, WE REVIEW MULTIPLE MECHANISMS BY WHICH DRUGS ALTER THE TRANSCRIPTIONAL POTENTIAL OF GENES. THESE MECHANISMS RANGE FROM THE MOBILIZATION OR REPRESSION OF THE TRANSCRIPTIONAL MACHINERY - INCLUDING THE TRANSCRIPTION FACTORS DELTAFOSB, CYCLIC AMP-RESPONSIVE ELEMENT BINDING PROTEIN (CREB) AND NUCLEAR FACTOR-KAPPAB (NF-KAPPAB) - TO EPIGENETICS - INCLUDING ALTERATIONS IN THE ACCESSIBILITY OF GENES WITHIN THEIR NATIVE CHROMATIN STRUCTURE INDUCED BY HISTONE TAIL MODIFICATIONS AND DNA METHYLATION, AND THE REGULATION OF GENE EXPRESSION BY NON-CODING RNAS. INCREASING EVIDENCE IMPLICATES THESE VARIOUS MECHANISMS OF GENE REGULATION IN THE LASTING CHANGES THAT DRUGS OF ABUSE INDUCE IN THE BRAIN, AND OFFERS NOVEL INROADS FOR ADDICTION THERAPY. 2011 10 5857 25 SUBSTRATE-SPECIFIC BINDING OF 8-OXOGUANINE DNA GLYCOSYLASE 1 (OGG1) REPROGRAMS MUCOSAL ADAPTATIONS TO CHRONIC AIRWAY INJURY. RECENT ADVANCES HAVE UNCOVERED THE NON-RANDOM DISTRIBUTION OF 7, 8-DIHYDRO-8-OXOGUANINE (8-OXOGUA) INDUCED BY REACTIVE OXYGEN SPECIES, WHICH IS BELIEVED TO HAVE EPIGENETIC EFFECTS. ITS COGNATE REPAIR PROTEIN, 8-OXOGUANINE DNA GLYCOSYLASE 1 (OGG1), READS OXIDATIVE SUBSTRATES AND PARTICIPATES IN TRANSCRIPTIONAL INITIATION. WHEN REDOX SIGNALING IS ACTIVATED IN SMALL AIRWAY EPITHELIAL CELLS, THE DNA REPAIR FUNCTION OF OGG1 IS REPURPOSED TO TRANSMIT ACUTE INFLAMMATORY SIGNALS ACCOMPANIED BY CELL STATE TRANSITIONS AND MODIFICATION OF THE EXTRACELLULAR MATRIX. EPITHELIAL-MESENCHYMAL AND EPITHELIAL-IMMUNE INTERACTIONS ACT COOPERATIVELY TO ESTABLISH A LOCAL NICHE THAT INSTRUCTS THE MUCOSAL IMMUNE LANDSCAPE. IF THE TRANSITIONAL CELL STATE GOVERNED BY OGG1 REMAINS RESPONSIVE TO INFLAMMATORY MEDIATORS INSTEAD OF DIFFERENTIATION, THE COLLATERAL DAMAGE PROVIDES POSITIVE FEEDBACK TO INFLAMMATION, ASCRIBING INFLAMMATORY REMODELING TO ONE OF THE DRIVERS IN CHRONIC PATHOLOGIES. IN THIS REVIEW, WE DISCUSS THE SUBSTRATE-SPECIFIC READ THROUGH OGG1 HAS EVOLVED IN REGULATING THE INNATE IMMUNE RESPONSE, CONTROLLING ADAPTATIONS OF THE AIRWAY TO ENVIRONMENTAL AND INFLAMMATORY INJURY, WITH A FOCUS ON THE READER FUNCTION OF OGG1 IN INITIATION AND PROGRESSION OF EPITHELIAL TO MESENCHYMAL TRANSITIONS IN CHRONIC PULMONARY DISEASE. 2023 11 3865 32 JAK2 REGULATES MISMATCH REPAIR PROTEIN-MEDIATED EPIGENETIC ALTERATIONS IN RESPONSE TO OXIDATIVE DAMAGE. AT SITES OF CHRONIC INFLAMMATION EPITHELIAL CELLS UNDERGO ABERRANT DNA METHYLATION THAT CONTRIBUTES TO TUMORIGENESIS. INFLAMMATION IS ASSOCIATED WITH AN INCREASE IN REACTIVE OXYGEN SPECIES (ROS) THAT CAUSE OXIDATIVE DNA DAMAGE, WHICH HAS ALSO BEEN LINKED TO EPIGENETIC ALTERATIONS. WE PREVIOUSLY DEMONSTRATED THAT IN RESPONSE TO ROS, MISMATCH REPAIR PROTEINS MSH2 AND MSH6 RECRUIT EPIGENETIC SILENCING PROTEINS DNA METHYLTRANSFERASE 1 (DNMT1) AND POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) MEMBERS TO SITES OF DNA DAMAGE, RESULTING IN TRANSCRIPTIONAL REPRESSION OF TUMOR SUPPRESSOR GENES (TSGS). HOWEVER, IT WAS UNCLEAR WHAT SIGNAL IS UNIQUE TO ROS THAT RESULTS IN THE CHROMATIN BINDING OF MSH2 AND MSH6. HEREIN, WE DEMONSTRATE THAT IN RESPONSE TO HYDROGEN PEROXIDE (H(2) O(2) ), JAK2 LOCALIZES TO THE NUCLEUS AND INTERACTS WITH MSH2 AND MSH6. INHIBITION OR KNOCKDOWN OF JAK2 REDUCES THE H(2) O(2) -INDUCED CHROMATIN INTERACTION OF MSH2, MSH6, DNMT1, AND PRC2 MEMBERS, REDUCES H(2) O(2) -INDUCED GLOBAL INCREASE IN TRIMETHYLATION OF LYSINE 27 OF HISTONE H3 (H3K27ME3), AND ABROGATES OXIDATIVE DAMAGE-INDUCED TRANSCRIPTIONAL REPRESSION OF CANDIDATE TSGS. MOREOVER, JAK2 MRNA EXPRESSION IS ASSOCIATED WITH CPG ISLAND METHYLATOR PHENOTYPE (CIMP) STATUS IN HUMAN COLORECTAL CANCER. OUR FINDINGS PROVIDE NOVEL INSIGHT INTO THE CONNECTION BETWEEN KINASE ACTIVATION AND EPIGENETIC ALTERATIONS DURING OXIDATIVE DAMAGE AND INFLAMMATION. ENVIRON. MOL. MUTAGEN. 60:308-319, 2019. (C) 2018 WILEY PERIODICALS, INC. 2019 12 636 37 BIOLOGICAL SUBSTRATES OF ADDICTION. THIS REVIEW IS AN INTRODUCTION TO ADDICTION, THE REWARD CIRCUITRY, AND LABORATORY ADDICTION MODELS. ADDICTION IS A CHRONIC DISEASE HALLMARKED BY A STATE OF COMPULSIVE DRUG SEEKING THAT PERSISTS DESPITE NEGATIVE CONSEQUENCES. MOST OF THE ADVANCES IN ADDICTION RESEARCH HAVE CENTERED ON THE CANONICAL AND CONTEMPORARY DRUGS OF ABUSE; HOWEVER, ADDICTIONS TO OTHER ACTIVITIES AND STIMULI ALSO EXIST. SUBSTANCES OF ABUSE HAVE THE POTENTIAL TO INDUCE LONG-LASTING CHANGES IN THE BRAIN AT THE BEHAVIORAL, CIRCUIT, AND SYNAPTIC LEVELS. ADDICTION-RELATED BEHAVIORAL CHANGES INVOLVE INITIATION, ESCALATION, AND OBSESSION TO DRUG SEEKING AND MUCH OF THE CURRENT RESEARCH IS FOCUSED ON MAPPING THESE MANIFESTATIONS TO SPECIFIC NEURAL PATHWAYS. DRUG ABUSE IS WELL KNOWN TO RECRUIT COMPONENTS OF THE MESOLIMBIC DOPAMINE SYSTEM, INCLUDING THE NUCLEUS ACCUMBENS AND VENTRAL TEGMENTAL AREA. IN ADDITION, ALTERED FUNCTION OF A WIDE VARIETY OF BRAIN REGIONS IS TIGHTLY ASSOCIATED WITH SPECIFIC MANIFESTATIONS OF DRUG ABUSE. THESE REGIONS PERIPHERAL TO THE MESOLIMBIC PATHWAY LIKELY PLAY A ROLE IN SPECIFIC OBSERVED COMORBIDITIES AND ENDOPHENOTYPES THAT CAN FACILITATE, OR BE CAUSED BY, SUBSTANCE ABUSE. ALTERATIONS IN SYNAPTIC STRUCTURE, FUNCTION, AND CONNECTIVITY, AS WELL AS EPIGENETIC AND GENETIC MECHANISMS ARE THOUGHT TO UNDERLIE THE PATHOLOGIES OF ADDICTION. IN PRECLINICAL MODELS, THESE PERSISTENT CHANGES ARE STUDIED AT THE LEVELS OF MOLECULAR PHARMACOLOGY AND BIOCHEMISTRY, EX VIVO AND IN VIVO ELECTROPHYSIOLOGY, RADIOGRAPHY, AND BEHAVIOR. COORDINATING RESEARCH EFFORTS ACROSS THESE DISCIPLINES AND EXAMINING CELL TYPE- AND CIRCUIT-SPECIFIC PHENOMENA ARE CRUCIAL COMPONENTS FOR TRANSLATING PRECLINICAL FINDINGS TO VIABLE MEDICAL INTERVENTIONS THAT EFFECTIVELY TREAT ADDICTION AND RELATED DISORDERS. WIRES COGN SCI 2014, 5:151-171. DOI: 10.1002/WCS.1273 CONFLICT OF INTEREST: THE AUTHORS HAVE DECLARED NO CONFLICTS OF INTEREST FOR THIS ARTICLE. FOR FURTHER RESOURCES RELATED TO THIS ARTICLE, PLEASE VISIT THE WIRES WEBSITE. 2014 13 2868 31 FUNCTIONAL CONSEQUENCES OF CALCIUM-DEPENDENT SYNAPSE-TO-NUCLEUS COMMUNICATION: FOCUS ON TRANSCRIPTION-DEPENDENT METABOLIC PLASTICITY. IN THE NERVOUS SYSTEM, CALCIUM SIGNALS PLAY A MAJOR ROLE IN THE CONVERSION OF SYNAPTIC STIMULI INTO TRANSCRIPTIONAL RESPONSES. SIGNAL-REGULATED GENE TRANSCRIPTION IS FUNDAMENTAL FOR A RANGE OF LONG-LASTING ADAPTIVE BRAIN FUNCTIONS THAT INCLUDE LEARNING AND MEMORY, STRUCTURAL PLASTICITY OF NEURITES AND SYNAPSES, ACQUIRED NEUROPROTECTION, CHRONIC PAIN, AND ADDICTION. IN THIS REVIEW, WE SUMMARIZE THE DIVERSE MECHANISMS GOVERNING CALCIUM-DEPENDENT TRANSCRIPTIONAL REGULATION ASSOCIATED WITH CENTRAL NERVOUS SYSTEM PLASTICITY. WE FOCUS ON RECENT ADVANCES IN THE FIELD OF SYNAPSE-TO-NUCLEUS COMMUNICATION THAT INCLUDE STUDIES OF THE SIGNAL-REGULATED TRANSCRIPTOME IN HUMAN NEURONS, IDENTIFICATION OF NOVEL REGULATORY MECHANISMS SUCH AS ACTIVITY-INDUCED DNA DOUBLE-STRAND BREAKS, AND THE IDENTIFICATION OF NOVEL FORMS OF ACTIVITY- AND TRANSCRIPTION-DEPENDENT ADAPTATIONS, IN PARTICULAR, METABOLIC PLASTICITY. WE SUMMARIZE THE RECIPROCAL INTERACTIONS BETWEEN DIFFERENT KINDS OF NEUROADAPTATIONS AND HIGHLIGHT THE EMERGING ROLE OF ACTIVITY-REGULATED EPIGENETIC MODIFIERS IN GATING THE INDUCIBILITY OF SIGNAL-REGULATED GENES. 2020 14 596 43 BET PROTEINS: AN APPROACH TO FUTURE THERAPIES IN TRANSPLANTATION. IN ORDER TO DEVELOP NEW EFFICIENT THERAPIES FOR ORGAN TRANSPLANTATION, IT IS ESSENTIAL TO ACQUIRE A COMPREHENSIVE KNOWLEDGE OF THE MOLECULAR MECHANISMS AND PROCESSES, SUCH AS IMMUNE ACTIVATION, CHRONIC INFLAMMATION, AND FIBROSIS, WHICH LEAD TO REJECTION AND LONG-TERM GRAFT LOSS. RECENT EFFORTS HAVE SHED SOME LIGHT ON THE EPIGENETIC REGULATION ASSOCIATED WITH THESE PROCESSES. IN THIS CONTEXT, THE BROMO AND EXTRATERMINAL (BET) FAMILY OF BROMODOMAIN PROTEINS (BRD2, BRD3, BRD4, AND BRDT) HAVE EMERGED AS MAJOR EPIGENETIC PLAYERS, CONNECTING CHROMATIN STRUCTURE WITH GENE EXPRESSION CHANGES. THESE PROTEINS RECOGNIZE ACETYLATED LYSINES IN HISTONES AND MASTER TRANSCRIPTION FACTORS TO RECRUIT REGULATORY COMPLEX AND, FINALLY, MODIFY THE TRANSCRIPTIONAL PROGRAM. RECENT STUDIES INDICATE THAT BET PROTEINS ARE ESSENTIAL IN THE NF-KB-MEDIATED INFLAMMATORY RESPONSE, DURING THE ACTIVATION AND DIFFERENTIATION OF TH17-IMMUNE CELLS, AND IN PROFIBROTIC PROCESSES. HERE, WE REVIEW THIS NEW BODY OF DATA AND HIGHLIGHT THE EFFICIENCY OF BET INHIBITORS IN SEVERAL MODELS OF DISEASES. THE PROMISING RESULTS OBTAINED FROM THESE PRECLINICAL MODELS INDICATE THAT IT MAY BE TIME TO TRANSLATE THESE OUTCOMES TO THE TRANSPLANTATION FIELD, WHERE EPIGENETICS WILL BE OF INCREASING VALUE IN THE COMING YEARS. 2017 15 866 32 CHRONIC ACTIVATION OF MUC1-C IN WOUND REPAIR PROMOTES PROGRESSION TO CANCER STEM CELLS. THE MUCIN 1 (MUC1) GENE EMERGED IN MAMMALS TO AFFORD PROTECTION OF BARRIER EPITHELIAL TISSUES FROM THE EXTERNAL ENVIRONMENT. MUC1 ENCODES A TRANSMEMBRANE C-TERMINAL (MUC1-C) SUBUNIT THAT IS ACTIVATED BY LOSS OF HOMEOSTASIS AND INDUCES INFLAMMATORY, PROLIFERATIVE, AND REMODELING PATHWAYS ASSOCIATED WITH WOUND REPAIR. AS A CONSEQUENCE, CHRONIC ACTIVATION OF MUC1-C PROMOTES LINEAGE PLASTICITY, EPIGENETIC REPROGRAMMING, AND CARCINOGENESIS. IN DRIVING CANCER PROGRESSION, MUC1-C IS IMPORTED INTO THE NUCLEUS, WHERE IT INDUCES NF-KAPPAB INFLAMMATORY SIGNALING AND THE EPITHELIAL-MESENCHYMAL TRANSITION (EMT). MUC1-C REPRESSES GENE EXPRESSION BY ACTIVATING (I) DNA METHYLTRANSFERASE 1 (DNMT1) AND DNMT3B, (II) POLYCOMB REPRESSIVE COMPLEX 1 (PRC1) AND PRC2, AND (III) THE NUCLEOSOME REMODELING AND DEACETYLASE (NURD) COMPLEX. PRC1/2-MEDIATED GENE REPRESSION IS COUNTERACTED BY THE SWI/SNF CHROMATIN REMODELING COMPLEXES. MUC1-C ACTIVATES THE SWI/SNF BAF AND PBAF COMPLEXES IN CANCER STEM CELL (CSC) MODELS WITH THE INDUCTION OF GENOME-WIDE DIFFERENTIALLY ACCESSIBLE REGIONS AND EXPRESSED GENES. MUC1-C REGULATES CHROMATIN ACCESSIBILITY OF ENHANCER-LIKE SIGNATURES IN ASSOCIATION WITH THE INDUCTION OF THE YAMANAKA PLURIPOTENCY FACTORS AND RECRUITMENT OF JUN AND BAF, WHICH PROMOTE INCREASES IN HISTONE ACTIVATION MARKS AND OPENING OF CHROMATIN. THESE AND OTHER FINDINGS DESCRIBED IN THIS REVIEW HAVE UNCOVERED A PIVOTAL ROLE FOR MUC1-C IN INTEGRATING LINEAGE PLASTICITY AND EPIGENETIC REPROGRAMMING, WHICH ARE TRANSIENT IN WOUND REPAIR AND SUSTAINED IN PROMOTING CSC PROGRESSION. 2022 16 6806 25 [EPIGENETICS AND DRUG ADDICTION: A FOCUS ON MECP2 AND ON HISTONE ACETYLATION]. CHRONIC DRUG EXPOSURE ALTERS GENE EXPRESSION IN THE BRAIN, WHICH IS BELIEVED TO UNDERLIE COMPULSIVE DRUG SEEKING AND DRUG TAKING BEHAVIOR. RECENT EVIDENCE SHOWS THAT DRUG-INDUCED LONG-TERM NEUROADAPTATIONS IN THE BRAIN ARE MEDIATED IN PART BY EPIGENETIC MECHANISMS. BY REMODELING CHROMATIN, THIS TYPE OF REGULATION CONTRIBUTES TO DRUG-INDUCED SYNAPTIC PLASTICITY THAT TRANSLATES INTO BEHAVIORAL MODIFICATIONS. HOW DRUG-INDUCED ALTERATIONS IN DNA METHYLATION REGULATE GENE EXPRESSION IS REVIEWED HERE, WITH A FOCUS ON MECP2, A PROTEIN BINDING METHYLATED DNA. THE IMPORTANCE OF HISTONE MODIFICATIONS, ESPECIALLY ACETYLATION IS ALSO DISCUSSED, WITH AN EMPHASIS ON THE EFFECTS OF INHIBITORS OF HISTONE DEACETYLASES ON DRUG-INDUCED BEHAVIORAL CHANGES. THE PRECISE IDENTIFICATION OF THE EPIGENETIC MECHANISMS THAT ARE UNDER THE CONTROL OF DRUGS OF ABUSE MAY HELP TO UNCOVER NOVEL TARGETS FOR THE TREATMENT OF DRUG SEEKING AND RELAPSE. 2015 17 2280 39 EPIGENETIC REGULATION IN DRUG ADDICTION. THE INTERACTION BETWEEN ENVIRONMENTAL SIGNALS AND GENES HAS NOW TAKEN ON A CLEAR MOLECULAR FORM AS DEMONSTRATED BY STABLE CHANGES IN CHROMATIN STRUCTURE. THESE CHANGES OCCUR THROUGH ACTIVATION OR REPRESSION OF SPECIFIC GENE PROGRAMMES BY A COMBINATION OF CHROMATIN REMODELLING, ACTIVATION AND ENZYMATIC MODIFICATION OF DNA AND HISTONES AS WELL AS NUCLEOSOMAL SUBUNIT EXCHANGE. RECENT RESEARCH INVESTIGATING THE MOLECULAR MECHANISMS CONTROLLING DRUG-INDUCED TRANSCRIPTIONAL, BEHAVIOURAL AND SYNAPTIC ACTIVITY HAS SHOWN A DIRECT ROLE FOR CHROMATIN REMODELLING--TERMED AS EPIGENETIC REGULATION--OF NEURONAL GENE PROGRAMMES AND SUBSEQUENT ADDICTIVE BEHAVIOUR ARISING FROM IT. RECENT DATA SUGGEST THAT REPEATED EXPOSURE TO CERTAIN DRUGS PROMOTES CHANGES IN LEVELS OF HISTONE ACETYLATION, PHOSPHORYLATION AND METHYLATION, TOGETHER WITH ALTERATIONS IN DNA METHYLATION LEVELS IN THE NEURONS OF THE BRAIN REWARD CENTRE, LOCALISED IN THE NUCLEUS ACCUMBENS (NAC) REGION OF THE LIMBIC SYSTEM. THE COMBINATION OF ACETYLATING, PHOSPHORYLATING AND METHYLATING H3 AND H4 HISTONE TAILS ALTER CHROMATIN COMPACTION THEREBY PROMOTING ALTERED LEVELS OF CELLULAR GENE EXPRESSION. HISTONE MODIFICATIONS, WHICH WEAKEN HISTONE INTERACTION WITH DNA OR THAT PROMOTE RECRUITMENT OF TRANSCRIPTIONAL ACTIVATING COMPLEXES, CORRELATE WITH PERMISSIVE GENE EXPRESSION. HISTONE DEACETYLATION, (WHICH STRENGTHEN HISTONE: DNA CONTACTS), OR HISTONE METHYLATION, (WHICH RECRUITS REPRESSIVE COMPLEXES TO CHROMATIN), PROMOTE A STATE OF TRANSCRIPTIONAL REPRESSION. USING ANIMAL MODELS, ACUTE COCAINE TREATMENT INCREASES H4 ACETYLATION AT ACUTELY REGULATED GENE PROMOTERS, WHEREAS H3 ACETYLATION APPEARS TO PREDOMINATE AT CHRONICALLY INDUCED PROMOTERS. CHRONIC COCAINE AND ALCOHOL TREATMENT ACTIVATE AND REPRESS MANY GENES SUCH AS FOSB, CDK5, AND BDNF, WHERE THEIR DYSREGULATION, AT THE CHROMATIN LEVEL, CONTRIBUTE TO THE DEVELOPMENT AND MAINTENANCE OF ADDICTION. FOLLOWING DRUG EXPOSURE, IT IS STILL UNKNOWN, HOWVER, HOW LONG THESE CHANGES IN CHROMATIN STRUCTURE PERSIST IN AFFECTING NEURONAL FUNCTION, BUT SOME DO SO FOR LIFE. 2012 18 2513 25 EPIGENETICS AND PSYCHOSTIMULANT ADDICTION. CHRONIC DRUG EXPOSURE ALTERS GENE EXPRESSION IN THE BRAIN AND PRODUCES LONG-TERM CHANGES IN NEURAL NETWORKS THAT UNDERLIE COMPULSIVE DRUG TAKING AND SEEKING. EXACTLY HOW DRUG-INDUCED CHANGES IN SYNAPTIC PLASTICITY AND SUBSEQUENT GENE EXPRESSION ARE TRANSLATED INTO PERSISTENT NEUROADAPTATIONS REMAINS UNCLEAR. EMERGING EVIDENCE SUGGESTS THAT COMPLEX DRUG-INDUCED NEUROADAPTATIONS IN THE BRAIN ARE MEDIATED BY HIGHLY SYNCHRONIZED AND DYNAMIC PATTERNS OF GENE REGULATION. RECENTLY, IT HAS BECOME CLEAR THAT EPIGENETIC MECHANISMS CONTRIBUTE TO DRUG-INDUCED STRUCTURAL, SYNAPTIC, AND BEHAVIORAL PLASTICITY BY REGULATING EXPRESSION OF GENE NETWORKS. HERE WE REVIEW HOW ALTERATIONS IN HISTONE MODIFICATIONS, DNA METHYLATION, AND MICRORNAS REGULATE GENE EXPRESSION AND CONTRIBUTE TO PSYCHOSTIMULANT ADDICTION WITH A FOCUS ON THE EPIGENETIC MECHANISMS THAT REGULATE BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) EXPRESSION FOLLOWING CHRONIC COCAINE EXPOSURE. IDENTIFYING EPIGENETIC SIGNATURES THAT DEFINE PSYCHOSTIMULANT ADDICTION MAY LEAD TO NOVEL, EFFICACIOUS TREATMENTS FOR DRUG CRAVING AND RELAPSE. 2013 19 2055 34 EPIGENETIC CONTROL DURING LYMPHOID DEVELOPMENT AND IMMUNE RESPONSES: ABERRANT REGULATION, VIRUSES, AND CANCER. METHYLATION OF CYTOSINES CONTROLS A NUMBER OF BIOLOGIC PROCESSES SUCH AS IMPRINTING AND X CHROMOSOMAL INACTIVATION. DNA HYPERMETHYLATION IS CLOSELY ASSOCIATED WITH TRANSCRIPTIONAL SILENCING, WHILE DNA HYPOMETHYLATION IS ASSOCIATED WITH TRANSCRIPTIONAL ACTIVATION. HYPOACETYLATION OF HISTONES LEADS TO COMPACT CHROMATIN WITH REDUCED ACCESSIBILITY TO THE TRANSCRIPTIONAL MACHINERY. METHYL-CPG BINDING PROTEINS CAN RECRUIT COREPRESSORS AND HISTONE DEACETYLASES; THUS, THE INTERPLAY BETWEEN THESE EPIGENETIC MECHANISMS REGULATES GENE ACTIVATION. METHYLATION HAS BEEN IMPLICATED AS AN IMPORTANT MECHANISM DURING IMMUNE DEVELOPMENT, CONTROLLING VDJ RECOMBINATION, LINEAGE-SPECIFIC EXPRESSION OF CELL SURFACE ANTIGENS, AND TRANSCRIPTIONAL REGULATION OF CYTOKINE GENES DURING IMMUNE RESPONSES. ABERRATIONS IN EPIGENETIC MACHINERY, EITHER BY GENETIC MUTATIONS OR BY SOMATIC CHANGES SUCH AS VIRAL INFECTIONS, ARE ASSOCIATED WITH EARLY ALTERATIONS IN CHRONIC DISEASES SUCH AS IMMUNODEFICIENCY AND CANCER. 2003 20 6802 21 [EPIGENETIC MECHANISMS IN MODELS OF CHRONIC PAIN - A TARGET FOR NOVEL THERAPY?]. EVIDENCE OF EPIGENETICS' ROLE IN PAIN RESPONSE IS ACCUMULATING IN RECENT YEARS. TIGHTLY REGULATED EPIGENETIC ALTERATIONS ON DNA AND HISTONES IN THE SENSORY CIRCUIT SHAPE THE PHYSIOLOGICAL RESPONSE TO INJURY. ALTERING THOSE EPIGENETIC PROCESSES HINDERS THERAPEUTIC POTENTIAL IN PAIN. THIS REVIEW PROVIDES AN OVERVIEW OF EPIGENOMIC MODIFICATION IN THE DEVELOPMENT OF CHRONIC PAIN, AND SUMMARIZES THE THERAPEUTIC POTENTIAL TO ALTER EPIGENETIC PROCESSES. 2018